Clinical Trial

Anti-Rheumatic Drug when Others Have not Worked

Study Description

A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Biological - placebo for rizankizumab

Placebo for risankizumab administered by subcutaneous (SC) injection

Biological - risankizumab

Risankizumab administered by subcutaneous (SC) injection

Additional Information

Official Study Title

A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Clinical Trial ID

NCT03675308

ParticipAid ID

e739re